rapid
optim
antimicrobi
chemotherapi
given
pediatr
patient
communityacquir
pneumonia
use
pcr
techniqu
serolog
standard
cultur
tive
pneumonia
c
pneumonia
infect
azithromycin
minocyclin
initi
use
treatment
averag
day
empir
chemotherapi
improp
case
relat
etiolog
agent
fi
nalli
identifi
ed
conclud
rapid
comprehens
identifi
cation
use
pcr
provid
optim
antimicrobi
chemotherapi
cap
patient
abstract
children
n
mean
age
year
diagnos
communityacquir
pneumonia
cap
use
clinic
symptom
chest
xray
hematolog
data
caus
pathogen
determin
use
realtim
polymeras
chain
reaction
pcr
bacteria
multipl
revers
transcriptionpcr
mpcr
virus
bacteri
cultur
serolog
initi
chemotherapi
evalu
base
pathogen
identifi
ed
use
pcr
found
viral
case
bacteri
case
mix
infect
viru
bacteria
mycoplasma
pneumonia
mix
infect
pneumonia
anoth
pathogen
chlamydophila
pneumonia
unknown
pathogen
streptococcu
pneumonia
haemophilu
infl
uenza
account
case
respect
median
valu
white
blood
cell
count
wbc
creactiv
protein
crp
use
boxandwhisk
plot
method
respect
mm
mgdl
viral
infect
mm
mgdl
mix
infect
viru
bacteria
mm
mgdl
bacteri
infect
mm
mgdl
pneumonia
infect
mm
mgdl
mix
infect
pneumonia
bacteri
infect
sulbactam
ampicillin
n
carbapenem
n
ceftriaxon
n
select
patient
suspect
bacteri
infect
alon
mix
infect
bacteri
virus
accord
criteria
defi
ned
tenta
communityacquir
pneumonia
cap
one
common
infect
occur
children
cap
caus
multipl
etiolog
agent
includ
virus
streptococcu
pneumonia
haemophilu
infl
uenza
mycoplasma
pneumonia
chlamydophila
pneumonia
agent
rate
caus
microorgan
quit
differ
depend
mani
factor
includ
detect
method
season
epidem
antibiot
predominantli
use
japan
antimicrobi
chemotherapi
patient
cap
begun
empir
base
chest
xray
clinic
fi
nding
includ
respiratori
statu
age
laboratori
test
white
blood
cell
count
wbc
creactiv
protein
concentr
crp
recent
guidelin
optim
empir
chemotherapi
cap
patient
publish
howev
believ
goal
chemotherapi
select
appropri
antibiot
everi
patient
within
short
time
admiss
base
laboratori
result
immedi
determin
caus
agent
recent
detect
virus
bacteria
use
polymeras
chain
reaction
pcr
addit
serolog
diagnosi
determin
etiolog
agent
high
precis
children
cap
determin
caus
pathogen
diffi
cult
diffi
culti
collect
direct
clinic
sampl
alveoli
unlik
adult
pathogen
must
identifi
ed
use
indirect
nasopharyng
sampl
low
invas
physician
determin
whether
isol
microorgan
etiolog
agent
therefor
system
estim
caus
pathogen
use
obtain
clinic
sampl
day
hospit
need
quickli
select
appropri
chemotherapi
aim
use
multiplex
pcr
mpcr
virus
parallel
bacteri
detect
use
realtim
pcr
nasopharyng
sampl
obtain
patient
pediatr
cap
convent
bacteri
cultur
use
sampl
serolog
diagnosi
pair
sera
patient
perform
verifi
result
pcr
clinic
fi
nding
laboratori
test
result
patient
compar
everi
caus
pathogen
appropri
antimicrobi
agent
select
empir
accord
clinic
fi
nding
evalu
pediatr
patient
cap
male
n
femal
n
admit
pediatr
depart
hakujikai
memori
hospit
tokyo
may
april
criteria
hospit
presenc
pulmonari
infi
ltrate
found
chest
xray
acut
respiratori
symptom
eg
tachypnea
deterior
gener
clinic
state
exclud
patient
requir
intens
therapi
includ
artifi
cial
ventil
chronic
respiratori
diseas
congenit
heart
diseas
hospit
diseas
within
period
patient
congenit
acquir
immunosuppress
condit
identifi
cation
caus
pathogen
inform
consent
obtain
child
parent
guardian
blood
sampl
taken
determin
wbc
crp
serum
antibodi
titer
sever
pathogen
nasopharyng
sampl
also
collect
determin
caus
pathogen
sampl
use
realtim
pcr
screen
six
bacteri
pathogen
multiplerevers
transcript
pcr
mpcr
screen
viral
pathogen
convent
bacteri
cultur
techniqu
perform
immedi
collect
sampl
laboratori
molecular
epidemiolog
infecti
agent
kitasato
institut
life
scienc
streptococcu
pneumonia
haemophilu
infl
uenza
mycoplasma
pneumonia
chlamydophila
pneumonia
streptococcu
pyogen
legionella
pneumophila
identifi
ed
within
h
use
realtim
pcr
rti
kit
takara
bio
kyoto
japan
stratagen
stratagen
la
jolla
ca
usa
sensit
specifi
citi
high
respect
compar
standard
cultur
previous
describ
identifi
cation
virus
mpcr
kit
maximbio
san
francisco
ca
usa
use
accord
manufactur
instruct
mpcr
kit
identifi
es
seven
virus
respiratori
syncyti
viru
rsv
adenoviru
adeno
infl
uenza
viru
flua
infl
uenza
viru
b
flub
parainfl
uenza
addit
four
primer
set
identifi
rhinoviru
rhino
human
metapneumoviru
hmpv
human
bocaviru
hbov
coronaviru
prepar
pcr
perform
use
condit
use
mpcr
kit
mpcr
requir
h
bacteri
cultur
perform
accord
manual
clinic
microbiolog
serotyp
pneumonia
perform
use
antiserum
purchas
staten
serum
institut
denmark
antibodi
titer
pneumonia
c
pneumonia
rsv
adeno
flua
flub
determin
pair
sera
acut
convalesc
phase
use
complement
fi
xation
cf
test
hemagglutin
inhibit
hi
test
enzymelink
immunosorb
assay
elisa
signifi
cant
rise
antibodi
titer
note
convalesc
phase
correspond
microorgan
consid
caus
pathogen
fourfold
rise
titer
pneumonia
adeno
rsv
use
cf
assay
flua
flub
use
hi
assay
use
indic
chlamydophila
pneumonia
diagnos
use
elisa
identifi
ed
patient
index
valu
id
igg
pair
sera
decis
begin
antimicrobi
chemotherapi
base
four
condit
describ
previous
clinic
cours
chest
xray
fi
nding
age
laboratori
fi
nding
clinic
observ
use
presenc
absenc
time
fever
respiratori
symptom
tachypnea
wheez
retract
breath
presenc
absenc
nasal
discharg
properti
recurr
fever
period
recoveri
common
coldlik
symptom
diagnosi
tachypnea
use
world
health
organ
criteria
chest
xray
divid
typic
pneumonia
segment
bronchial
pneumonia
atyp
pneumonia
groundglass
appear
skip
lesion
pleurisi
segment
viral
pneumonia
bronchial
pneumonia
interstiti
shadow
regard
age
patient
age
year
older
usual
thought
pneumonia
infect
age
year
younger
viral
mix
viral
bacteri
infect
bacteri
infect
mix
infect
suspect
patient
age
year
younger
wbc
count
mm
greater
crp
valu
mgdl
greater
valu
may
low
case
earli
stage
onset
wbc
may
readili
fl
uctuat
variou
reason
infant
howev
ultim
estim
infect
bacteri
viral
mycoplasm
mix
determin
use
composit
clinic
cours
chest
xray
age
laboratori
data
four
parenter
antibiot
ampicillinsulbactam
sbtabpc
panipenem
papm
meropenem
mepm
ceftriaxon
ctrx
singl
agent
select
patient
suspect
bacteri
infect
alon
viralbacteri
mix
infect
four
condit
describ
respect
dose
follow
sbtabpc
mg
kg
day
qid
papm
mepm
mg
kg
day
tid
ctrx
mg
kg
day
bid
antibiot
administ
day
defervesc
febril
period
vari
consider
patient
viral
bacteri
mix
infect
antibiot
withdrawn
day
defervesc
judg
antibiot
effect
bacteri
pathogen
patient
suspect
pneumonia
c
pneumonia
infect
four
condit
azithromycin
azm
minocyclin
mino
use
use
antimicrobi
agent
patient
viral
infect
alon
strongli
suggest
four
condit
describ
criteria
etiolog
classifi
cation
tabl
show
tent
criteria
etiolog
classifi
cation
cap
patient
seven
categori
follow
bacteri
mix
infect
viral
bacteri
viral
mycoplasm
mix
infect
mycoplasm
chlamydi
bacteri
mix
infect
mycoplasm
chlamydi
viral
unknown
could
identifi
etiolog
agent
statist
analysi
differ
clinic
fi
nding
relat
caus
pathogen
perform
use
fisher
exact
test
wbc
crp
valu
day
admiss
analyz
use
boxandwhisk
plot
method
lower
hing
median
upper
hing
box
correspond
percentil
respect
half
case
includ
box
dot
line
box
time
quartil
deviat
one
hundr
seventeen
cap
case
male
femal
patient
may
april
describ
previous
decis
admit
determin
use
chest
xray
ie
segment
pneumonia
bronchial
pneumonia
atyp
pneumonia
interstiti
shadow
acut
respiratori
symptom
deterior
gener
state
fiftyeight
case
previous
receiv
oral
antimicrobi
agent
within
week
prior
hospit
viral
pathogen
mpcr
virus
correl
serolog
test
result
tabl
pcr
posit
case
rsv
adeno
flua
flub
show
signifi
cantli
high
antibodi
titer
correspond
viru
specifi
citi
pcr
agent
howev
sensit
pcr
viral
infect
alon
mix
infect
simultan
infect
two
virus
adeno
rsv
hmpv
identifi
ed
two
patient
cumul
posit
case
determin
serolog
pcr
rsv
case
adeno
flua
flub
rhino
hmpv
case
case
corona
hbov
infect
identifi
ed
bacteria
suspect
caus
pathogen
determin
standard
cultur
realtim
pcr
six
pathogen
streptococcu
pneumonia
haemophilu
infl
uenza
mycoplasma
pneumonia
chlamydophila
pneumonia
streptococcu
pyogen
legionella
pneumophila
tabl
patient
suspect
infect
caus
pneumonia
h
infl
uenza
realtim
pcr
result
posit
earli
threshold
cycl
indic
cfu
per
sampl
direct
bacteri
count
show
cfu
per
sampl
use
standard
cultur
found
time
respect
pneumonia
h
infl
uenza
seventeen
case
identifi
ed
pneumonia
infect
show
singl
ten
case
mix
seven
case
infect
microorgan
fourteen
case
identifi
ed
rapidli
realtim
pcr
rate
individu
pathogen
patient
distribut
age
shown
fig
viral
infect
mix
infect
virus
bacteria
frequent
among
children
month
year
age
bacteri
infect
alon
occur
age
year
pneumonia
occur
age
year
older
clinic
characterist
accord
etiolog
agent
tabl
follow
clinic
fi
nding
admiss
classifi
ed
accord
respect
criteria
chest
xray
fi
nding
withwithout
asthma
respir
rate
wbc
crp
analyz
statist
use
fisher
exact
test
expect
signifi
cant
differ
note
chest
xray
among
fi
group
sign
interstiti
pneumonia
frequent
found
patient
viral
infect
segment
pneumonia
bacteri
infect
bronchial
segment
pneumonia
mix
infect
atyp
pneumonia
patient
pneumonia
infect
viral
infect
viral
bacteri
mix
infect
frequent
children
asthma
compar
infect
regard
respiratori
rate
tachypnea
observ
pneumonia
infect
wbc
crp
differ
signifi
cantli
viral
bacteri
infect
bacteri
mix
pneumonia
group
wbc
crp
valu
compar
caus
pathogen
wbc
crp
valu
patient
day
admiss
plot
accord
respect
caus
pathogen
fig
patient
unclear
caus
pathogen
n
c
pneumonia
n
mix
infect
pneumonia
viru
n
exclud
data
analyz
use
boxandwhisk
plot
method
box
encompass
case
shown
fig
median
wbc
valu
patient
viral
viral
bacteri
bacteri
pneumonia
pneumonia
bacteri
infect
mm
respect
patient
defi
ned
viral
bacteri
mix
infect
box
wbc
valu
locat
viral
bacteri
case
shown
fig
relat
empir
select
antibiot
case
caus
pathogen
shown
tabl
decis
use
antimicrobi
select
criterion
initi
treatment
outlin
patient
method
antibiot
use
patient
name
sbtabpc
ctrx
carbapenem
either
mepm
papm
azm
mino
sbtabpc
azm
patient
antibiot
use
patient
initi
select
antibiot
retrospect
consid
inappropri
patient
viral
infect
adeno
rsv
infa
pneumonia
viral
mix
infect
patient
undetermin
caus
pathogen
case
antimicrobi
inappropri
use
case
clinic
defervesc
achiev
within
h
admiss
patient
bacteri
infect
averag
durat
antimicrobi
treatment
day
durat
antibiot
therapi
also
day
four
patient
pneumonia
h
infl
uenza
isol
blood
cultur
taken
admiss
termin
treatment
patient
experienc
relaps
refractori
treatment
howev
experienc
four
case
recurr
fever
whose
hospit
slightli
prolong
due
relaps
pneumonia
recov
spontan
without
antimicrobi
use
identifi
cation
caus
pathogen
children
cap
alway
easi
sputum
bronchoalveolar
lavag
bal
sampl
obtain
routin
perform
adult
diagnos
children
caus
pathogen
suspect
histori
chest
xray
blood
examin
data
take
account
patient
age
antibiot
select
empir
recent
japan
guidelin
treatment
manag
respiratori
tract
infect
pediatr
patient
propos
promot
optim
chemotherapi
similar
guidelin
found
countri
howev
incid
rate
pathogen
microorgan
pediatr
cap
countri
like
differ
due
mani
factor
health
insur
system
vaccin
program
kind
antibiot
predominantli
use
popul
densiti
publish
studi
use
pcr
method
determin
pathogen
cap
simultan
detect
bacteria
virus
expect
enhanc
accuraci
cap
diagnosi
aim
identifi
bacteria
virus
use
pcr
within
short
time
frame
evalu
pcr
result
relat
clinic
fi
nding
previous
describ
dnarna
sampl
extract
clini
near
futur
anticip
also
abl
accomplish
viral
identifi
cation
realtim
pcr
use
nasopharyng
sampl
sourc
identifi
caus
pathogen
materi
appropri
identifi
virus
mycoplasma
pneumonia
chlamydophila
pneumonia
sampl
type
question
streptococcu
pneumonia
haemophilu
infl
uenza
present
normal
individu
posit
result
pneumonia
h
infl
uenza
realtim
pcr
care
consid
whether
indic
causal
relat
infect
physician
consid
chest
xray
clinic
symptom
clinic
laboratori
fi
nding
wbc
crp
bacteri
amount
infl
ammat
fi
nding
leucocyt
nasopharyng
sampl
rate
virus
bacteria
identifi
ed
studi
caus
pathogen
similar
data
report
michelow
et
al
et
al
although
rate
h
infl
uenza
differ
presum
hib
vaccin
approv
japan
case
pneumonia
due
hib
nontyp
h
infl
uenza
three
cap
case
hib
posit
blood
cultur
posit
realtim
pcr
found
among
case
chlamydophila
pneumonia
detect
one
patient
possibl
children
older
year
studi
relat
diagnosi
cap
blood
examin
test
although
studi
conclud
crp
wbc
provid
use
inform
pneumococc
pneumonia
valu
use
japanes
pediatrician
use
refer
addit
routin
chest
xray
diagnos
pneumonia
clinic
practic
observ
valu
fl
uctuat
half
day
onset
bacteri
infect
addit
case
adenoviru
infect
viru
pneumonia
infect
schoolag
children
valu
wbc
crp
rel
high
physician
must
mind
kind
except
case
howev
shown
data
signifi
cant
differ
valu
found
correl
caus
pathogen
present
believ
time
onset
present
hospit
rel
uniform
japan
compar
countri
univers
health
insur
system
studi
antimicrobi
agent
empir
select
found
inappropri
administ
case
use
techniqu
found
treatment
case
complet
within
day
gener
dose
period
recommend
guidelin
day
howev
consid
somewhat
long
antibiot
act
caus
bacteria
within
shorter
period
strain
pneumonia
penicillin
resist
streptococcu
pneumonia
prsp
none
patient
experienc
relaps
treatment
sbtabpc
carbapenem
antibiot
data
shown
viral
bacteri
mix
infect
identifi
ed
case
addit
viral
infect
thu
involv
viralrel
case
case
total
furthermor
case
relat
viru
infect
may
present
could
demonstr
day
elaps
onset
time
acquir
clinic
sampl
also
import
demonstr
caus
virus
futur
expect
comprehens
rapid
identifi
cation
caus
pathogen
outlin
becom
routin
clinic
practic
